GLP-3R research

The GLP-3R evidence base cited here is 17 sources — 9 clinical, 1 preclinical, 4 review, 1 regulatory. Its strongest evidence is human — 9 clinical studies, most recently 2026 ("TRIUMPH-1 Pivotal Phase 3 Obesity Trial — 28.3% Weight Loss at 12 mg (To…"). Regulatory status: Not FDA-approved (Phase III).

Cross-trial comparison only — these drugs have not been tested head-to-head, and the populations, durations, and endpoints differ.

• GLP-3R (LY3437943) is an investigational triple-receptor agonist from Eli Lilly that activates the GLP-1, GIP, and glucagon receptors simultaneously — a mechanism no approved drug shares.
• The strongest peer-reviewed result is a 24.2% mean body-weight reduction at 48 weeks in the Phase 2 obesity trial (Jastreboff et al., NEJM 2023).
• Other Phase 3 topline figures (~28.7% at 68 weeks in TRIUMPH-4; ~16.8% weight loss and ~1.7–2.0-point HbA1c reductions in TRANSCEND-T2D-1) are likewise reported topline only and pending publication.

GLP-3R is an experimental peptide that Eli Lilly is developing for obesity, type 2 diabetes, and related metabolic disease. What sets it apart from the GLP-1 drugs already on the market is that it engages three metabolic receptors at once — GLP-1, GIP, and glucagon — rather than one or two.

Its receptor activity is GIP-primary. Reported EC50 values are about 0.064 nM at the GIP receptor (its most potent target), 0.78 nM at GLP-1, and 5.8 nM at glucagon. Combining all three signals in one molecule is the central bet of the program: each receptor contributes a different metabolic lever, and together they appear to do more than single- or dual-agonists can.

• Other GLP-1 agonists — not advisable; overlapping mechanisms raise GI-side-effect risk with little added benefit.
• Metformin — trials included participants on stable metformin, and the combination was well tolerated.
• Lifestyle (diet, resistance training, adequate protein) — trials paired the drug with diet and activity guidance; resistance training plus higher protein intake is the evidence-based way to limit the lean-mass loss seen with rapid weight reduction.

No GLP-3R-specific interaction studies are published; the considerations below are inferred from GLP-1-class pharmacology and are research context, not medical guidance.

• Oral medications, including oral contraceptives — delayed gastric emptying can slow or reduce absorption; timing and effectiveness monitoring are the standard precautions.
• Other GLP-1 / incretin agonists (GLP-1S, GLP-2T) — overlapping mechanisms; combining is not advisable.

The GLP-3R evidence base spans peer-reviewed publications and company-reported topline readouts. Peer-reviewed results are the higher-confidence tier; topline figures are preliminary until published.

• TRIUMPH-4 (obesity + knee osteoarthritis, 68 wk): ~28.7% weight loss with substantial osteoarthritis pain reduction — company-reported topline, pending publication.
• TRIUMPH-Outcomes (cardiovascular, ~10,000 participants with established ASCVD, ~5-year): assessing major adverse cardiovascular and kidney events — ongoing.

GLP-3R is not approved by the FDA or any regulatory agency. It is in active clinical development by Eli Lilly across three program families — TRIUMPH (obesity), TRANSCEND (type 2 diabetes), and SYNERGY (liver disease) — spanning roughly 19 trials and ~19,700 participants.

• TRIUMPH-4 (obesity + knee osteoarthritis): completed Dec 2025 — reported topline ~28.7% at 68 weeks, pending publication
• TRANSCEND-T2D-1 (type 2 diabetes): completed Mar 2026 — reported topline, pending publication
• TRIUMPH-2/3 and cardiovascular- and liver-outcome trials: ongoing through 2026 and beyond
• Projected NDA filing: ~Q4 2026–Q1 2027
• Most-cited approval estimate: late 2027 or 2028

Research-grade GLP-3R sold by peptide suppliers is for laboratory research only and is not intended for human use.

GLP-3R is not explicitly named on the 2026 WADA Prohibited List. However, GLP-1-class drugs have been on WADA's monitoring program since 2024, and an investigational metabolic agent like this could plausibly fall under metabolic-modulator or peptide-hormone categories. Athletes subject to testing should clear any use with their governing body first.

On the Huberman Lab podcast, Dr. Abud Bakri placed GLP-3R in the GLP-1 family that he believes could help relieve a strained medical system — while repeatedly asking 'is there a free lunch?' He emphasized that these drugs raise GLP-1 signaling on the order of 1000-fold (versus 2–4× for older diabetes drugs), with unknown effects on neuroplasticity and learning, especially in young people losing large amounts of weight.

Expert clinical opinion; GLP-3R is not FDA-approved, and the trial-efficacy figures elsewhere on this page are company-reported topline, pending peer review.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.